STEFANUTTI, Claudia
 Distribuzione geografica
Continente #
NA - Nord America 6.104
EU - Europa 1.846
AS - Asia 1.118
AF - Africa 85
SA - Sud America 49
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 9.208
Nazione #
US - Stati Uniti d'America 6.051
IT - Italia 609
SG - Singapore 449
UA - Ucraina 409
IN - India 408
SE - Svezia 268
CN - Cina 210
FI - Finlandia 209
DE - Germania 80
TG - Togo 79
GB - Regno Unito 70
CA - Canada 48
AR - Argentina 39
IE - Irlanda 38
NL - Olanda 33
RU - Federazione Russa 33
BG - Bulgaria 28
BE - Belgio 22
ID - Indonesia 20
RO - Romania 15
FR - Francia 9
HK - Hong Kong 8
CL - Cile 5
LT - Lituania 5
MX - Messico 5
AT - Austria 4
CH - Svizzera 4
EU - Europa 4
ZA - Sudafrica 4
ES - Italia 3
JP - Giappone 3
AE - Emirati Arabi Uniti 2
BR - Brasile 2
MY - Malesia 2
PK - Pakistan 2
SA - Arabia Saudita 2
TH - Thailandia 2
TR - Turchia 2
TW - Taiwan 2
UZ - Uzbekistan 2
AU - Australia 1
AZ - Azerbaigian 1
BO - Bolivia 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
IR - Iran 1
KR - Corea 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PL - Polonia 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
Totale 9.208
Città #
Fairfield 849
Woodbridge 540
Chandler 450
Houston 406
Ashburn 378
Ann Arbor 347
Singapore 309
Seattle 306
Wilmington 300
Cambridge 238
Princeton 222
Plano 191
San Paolo di Civitate 190
Rome 166
Jacksonville 156
Boston 142
Beijing 137
Santa Clara 129
Lawrence 123
Millbury 81
Lomé 79
San Diego 74
Fremont 63
Andover 61
Stockholm 48
Des Moines 43
Norwalk 41
Federal 39
Dublin 38
Dearborn 34
Toronto 29
Boardman 28
Sofia 28
New York 21
Brussels 20
Bühl 20
Falls Church 20
Jakarta 20
Chennai 18
Ottawa 18
Milan 16
Helsinki 13
Falkenstein 11
Moscow 11
Buffalo 10
London 10
Nanjing 10
Southend 9
Hefei 8
Mannheim 7
San Francisco 7
San Mateo 7
Bologna 6
Frankfurt am Main 6
Hong Kong 6
Indiana 6
Laurel 6
Redwood City 6
Ancona 5
Auburn Hills 5
Los Angeles 5
Redmond 5
Chicago 4
Dallas 4
Amsterdam 3
Bellevue 3
Florence 3
Kunming 3
Naples 3
Padova 3
Phoenix 3
Portland 3
Prineville 3
Quartu Sant'Elena 3
Santiago 3
Scalenghe 3
Tappahannock 3
Verona 3
Vienna 3
West Malling 3
Yellow Springs 3
Bagnolo Mella 2
Berlin 2
Bern 2
Caltanissetta 2
Chongqing 2
Como 2
Edinburgh 2
Ercolano 2
Faisalabad 2
Fuenlabrada 2
Genoa 2
Giugliano in Campania 2
Hebei 2
Hyderabad 2
Istanbul 2
Jeddah 2
Jinan 2
Kilburn 2
Las Vegas 2
Totale 6.674
Nome #
LDL-aferesi e aferesi selettiva 135
Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. 119
Toward an international consensus - integrating lipoprotein apheresis and new lipid-lowering drugs 108
Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis 105
First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias 88
LDL-apheresis in a homozygous familial hypercholesterolemic child aged 4.5 83
EXTRACORPOREAL ATHEROGENIC LIPOPROTEIN REMOVAL IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 82
Therapeutic apheresis in pregnancy: three differential indications with positive maternal and fetal outcome 82
Therapeutic apheresis in low weight patients: Technical feasibility, tolerance, compliance, and risks 80
Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score 79
Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort 78
Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report 77
THE NATURAL-HISTORY OF GALLSTONES - THE GREPCO EXPERIENCE 76
A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature 76
Effects of CER-001 on carotid atherosclerosis by 3TMRI in homozygous familial hypercholesterolemia (HoFH): the modifying orphan disease evaluation (MODE) study 75
Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis 75
THE GREPCO STUDIES - METHODOLOGY, PREVALENCE AND INCIDENCE DATA 74
Atorvastatin Inhibits gp91(phox) Circulating Levels in Patients With Hypercholesterolemia 74
Low-density lipoprotein apheresis in a patient aged 3.5 years. 73
Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. 72
Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk 71
Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia 71
Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. 71
A three month-old infant with severe hyperchylomicronemia: Molecular diagnosis and extracorporeal treatment 70
Association of serum selenium with selected cardiovascular risk factors 70
Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study 70
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - A post-hoc analysis of a Phase 3, single-arm, open-label trial 70
LDL-apheresis in pediatric patients with severe hyperlipoproteinemia 69
Identification and diagnosis of patients with familial chylomicronemia syndrome (FCS): Expert Panel recommendations and proposal of an FCS Score 69
A new missense mutation (Cys 297- - Phe) of the low density lipoprotein receptor in italian patients with familial hypercholesterolemia (FH Trieste) 69
The 2009 2nd Italian Consensus Conference on LDL-apheresis 68
A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report 68
Platelet activation in hypercholesterolemic patients submitted to therapeutic plasmapheresis. An ultrastructural study 68
Association of Serum Selenium with Selected Cardiovascular Risk Factors. 67
Italian Multicenter Study on Low-Density Lipoprotein Apheresis Working Group 2009 Survey 66
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study 66
A multi-centre study on completeness of urine collection in 11 European centres. Some problems with the use of creatinine and 4-aminobenzoic acid as marker of the com¬pleteness of collection 66
New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia 65
Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia 64
Hypertriglyceridaemia, Postprandial Lipaemia And Non-Hdl Cholesterol. 64
Prevalence of gallstone disease in an Italian adult female population. 63
Gemfibrozil alone and combined with cholestyramine in the treatment of primary hyperlipoproteinemia. 63
Immunoadsorption apheresis (Selesorb ©) in the treatment of chronic hepatitis C virus (HCV)- related type 2 mixed cryglobulinemia. 63
Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias 63
Hijacked journals are emerging as a challenge for scholarly publishing 63
Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion 63
Immunoadsorption Apheresis and Immunosuppressive Drug Therapy in the Treatment of Complicated HCV-Related Cryoglobulinemia 63
Therapeutic plasma exchange in patients with severe hypertriglyceridemia: A multicenter study 62
Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis 62
Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis 62
LIPOPROTEIN AND HEMOCOAGULATORY PARAMETERS DURING THERAPEUTIC PLASMAPHERESIS IN HOMOZYGOUS AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 62
Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis 62
ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia? 61
Aorta and Coronary Angiographic Follow-up of Children with Severe Hypercholesterolemia Treated with LDL Apheresis 60
SERUM-LIPIDS AND GALLSTONE DISEASE 60
Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia 60
Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. 60
Four novel partial deletions of LDL-receptor gene in Italian patients with familial hypercholesterolemia. 59
A new treatment of refractory ascites: Ascitoapheresis 59
Clinical Trials in Apheresis 58
LDL-apheresis in the treatment of familial hypercholesterolemia in childhood 57
Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care 56
Simvastatin and pravastatin: a daily dose of 40 mg in the long-term treatment of primary hypercholesterolemia. 56
Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia 56
Scientific Information Security in Information Science and Academic Publishing 55
Cyclophosphamide and immunoadsorption apheresis treatment of lupus nephritis nonresponsive to drug therapy alone 55
DALI low-density lipoprotein apheresis in homozygous and heterozygous familial hypercholesterolemic patients using low-dose citrate anticoagulation. 54
Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9 54
Differenze sessuali nel metabolismo dei lipidi e delle lipoproteine plasmatiche 54
Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL apheresis 53
Hypercholesterolemia alters the response of the plasma lipid profile and inflammatory markers to supplementation of the diet with n-3 polyunsaturated fatty acids from fish oil. 53
Different Hormonal Treatment In Pre- and Post-Menopausal Women: Effect on the Cardiovascular Risk 53
Obesity as a risk factor for gallstone disease: results of a six-years follow-up study. 53
Treatment of primary hypertriglyceridemia states - General approach and the role of extracorporeal methods 53
Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis. 52
Lipoprotein Apheresis: state of the art and novelties 52
Corticosteroidi prenatali: cosa c'è di nuovo? 52
The 1(st) and the 2(nd) Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update 52
EFFICACY OF ALIROCUMAB IN 1,191 PATIENTS WITH A WIDE SPECTRUM OF MUTATIONS IN GENES CAUSATIVE FOR FAMILIAL HYPERCHOLESTEROLEMIA 52
A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study 52
Pediatric LDL-apheresis: clinical experience in Italy’s largest sample. 51
A MULTICENTER STUDY ON COMPLETENESS OF URINE COLLECTION IN 11 EUROPEAN CENTERS .1. SOME PROBLEMS WITH THE USE OF CREATININE AND 4-AMINOBENZOIC ACID AS MARKERS OF THE COMPLETENESS OF COLLECTION 51
Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial 51
Severe hypertriglyceridemia-related acute pancreatitis: Myth or reality? 51
H.E.L.P. LDL-apheresis clinical experience in Italy 50
Severe Hypertriglyceridemia-Related Acute Pancreatitis 50
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia 50
Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a) 50
DEXTRAN SULFATE CELLULOSE LDL-AFFINITY APHERESIS IN THE TREATMENT OF SEVERE FAMILIAL HYPERCHOLESTEROLEMIA AND NONFAMILIAL HYPERLIPOPROTEINEMIA - A CLINICAL REPORT ON 12 CASES 49
Targeting MTP for the treatment of homozygous familial hypercholesterolemia 49
Lipid apheresis in secondary cardiovascular risk prevention in HyperLp(a)lipidemia. Why not?. 49
Comparison between different techniques of LDL-apheresis 48
Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia 48
The Italian Registry of Pediatric Therapeutic Apheresis: a concise report on the 2005 activity 48
THE ITALIAN MULTICENTER STUDY ON LDL-APHERESIS: RETROSPECTIVE ANALYSIS (2007) 47
Anticorpi agonisti del recettore dell’angiotensina II nell’ipertensione in gravidanza 47
Therapeutic Plasmapheresis. A gate to an effective treatment of severe pathological conditions 46
Prevalence of cholelithiasis in a female population and study of risk factors sex-related. 45
LDL-apheresis induced anti-oxidative modification of LDL 45
Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives 45
Totale 6.345
Categoria #
all - tutte 29.226
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.226


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.130 0 0 0 0 0 213 211 211 171 152 120 52
2020/2021796 82 86 23 60 10 100 3 107 110 129 71 15
2021/20221.977 5 128 165 78 269 58 37 214 146 165 312 400
2022/20231.736 388 481 80 116 171 163 28 88 155 11 48 7
2023/2024696 59 109 19 46 42 62 7 41 5 121 67 118
2024/2025746 70 73 155 125 163 160 0 0 0 0 0 0
Totale 9.537